Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib

摘要: Several cancer treatments are shifting from traditional, time-limited, nonspecific cytotoxic chemotherapy cycles to continuous oral treatment with specific protein-targeted therapies. In this line, imatinib mesylate, a selective tyrosine kinases inhibitor (TKI), has excellent efficacy in the of chronic myeloid leukemia. It opened way development additional TKIs against leukemia, including nilotinib and dasatinib. prescribed for prolonged periods, often patients comorbidities. Therefore, they regularly co-administered along at risk drug-drug interactions. This aspect been partially addressed so far, calling comprehensive review published data. We here available evidence pharmacologic mechanisms interactions between imatinib, dasatinib, widely co-medications, known inhibitors or inducers cytochromes P450 drug transporters. Information is mostly well introduced clinical practice. pharmacokinetic aspects yet remain insufficiently investigated these drugs. Regular updates will be mandatory prospective reporting unexpected observations.